AVIDITY Destiny 2
>> YOUR LINK HERE: ___ http://youtube.com/watch?v=T3G1mM6axyk
Defeat Duchenne Canada hosted an industry partner update recorded on Thursday, October 3. In this free webinar, Avidity Biosciences shared the initial data from the EXPLORE44 TM Clinical Trial. • Tune in to the evaluation of del-zota(formerly AOC 1044)for the treatment of individuals with Duchenne muscular dystrophy mutations amenable to exon 44 skipping (DMD44) • Hear more from our Industry Partners: https://defeatduchenne.ca/webinars/
#############################
